A meta-analysis on the efficacy and safety of St John’s wort extract in depression therapy in comparison with selective serotonin reuptake inhibitors in adults

@article{Cui2016AMO,
  title={A meta-analysis on the efficacy and safety of St John’s wort extract in depression therapy in comparison with selective serotonin reuptake inhibitors in adults},
  author={Yonghua Cui and Yi Zheng},
  journal={Neuropsychiatric Disease and Treatment},
  year={2016},
  volume={12},
  pages={1715 - 1723}
}
Objective The aim of the study was to investigate the efficacy and safety of St John’s wort extract and selective serotonin reuptake inhibitors (SSRIs) in the treatment of depression. Methods Databases were searched for studies comparing efficacy and/or safety of St John’s wort extract with SSRIs in depression from 1966 to April 2015. Stata software was used for statistical analysis. Results Twenty-seven studies met the study entry criteria. A total of 3,126 patients with depression were… Expand
Pharmacological and non-pharmacological treatments for major depressive disorder: review of systematic reviews
TLDR
The majority of non-pharmacological interventions for treating patients with MDD are not evidence based, and patients with strong preferences against pharmacological treatments should focus on therapies that have been compared directly with antidepressants. Expand
Complementary therapies for clinical depression: an overview of systematic reviews
TLDR
The effects of all but two CAM treatments found in studies on clinical depressed patients based on low to very low quality of evidence have to be downgraded mostly due to avoidable methodological flaws of both the original RCTs and meta-analyses not following the Consolidated Standards of Reporting Trials and Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Expand
St. John’s Wort-Induced Supraventricular Tachycardia
TLDR
A case of a 33-year-old female who presented with recurrent episodes of palpitations one month after initiating St. John’s wort for the treatment of depression, which ultimately resolved upon cessation of the herbal supplement, brings into question the safety of the use of this agent as an OTC supplement for the management of depression. Expand
Management of depressive symptoms in peri- and postmenopausal women: EMAS position statement.
TLDR
Although not approved for this indication, menopausal hormone therapy may improve depressive symptoms in perimenopausal but not in postmenopausal women, especially in those with vasomotor symptoms. Expand
A Balanced Risk-Benefit Analysis to Determine Human Risks Associated with Pyrrolizidine Alkaloids (PA)—The Case of Herbal Medicinal Products Containing St. John’s Wort Extracts (SJW)
TLDR
Evidence from clinical studies indicates that quantified SJW extract is an effective treatment option for mild to moderate depression with fewer side effects than conventional antidepressants and its potential of treating depression outweighs the (hypothetical) risk of unwanted PA intake. Expand
The safety of St John's wort (Hypericum perforatum) in pregnancy and lactation: A systematic review of rodent studies
TLDR
Critical appraisal with contemporary tools indicates that each of the reviewed studies lacks appropriate rigour, rendering the results unreliable, and these papers are used in the rationale for recommending or contraindicating SJW during pregnancy and lactation. Expand
It is time to investigate integrative approaches to enhance treatment outcomes for depression?
TLDR
It is argued that increased efforts should be directed at investigating integrative or adjunctive interventions, rather than stand-alone treatments, to enhance outcomes for depression. Expand
Nutritional psychiatry: the present state of the evidence
TLDR
Preliminary clinical evidence that dietary interventions in clinically diagnosed populations are feasible and can provide significant clinical benefit is provided, and nutraceuticals including n-3 fatty acids, folate, S-adenosylmethionine, N-acetyl cysteine and probiotics are promising avenues for future research. Expand
Changes in prevalence of psychotropic drug use and alcohol consumption among the elderly in Germany: results of two National Health Interview and Examination Surveys 1997-99 and 2008-11
TLDR
Prevalence of overall psychotropic drug use remained stable, changes in the use of some psychotropics groups and alcohol consumption patterns have been observed, and significant changes in benzodiazepines use are observed. Expand
Health Supplement Use and Related Adverse Events in Dubai, United Arab Emirates: A Cross-Study
TLDR
The purpose of this research was to measure the health supplement consumption in the population of Dubai, the adverse events thereof, and the level of knowledge, attitude, and practice among healthcare professionals about the issue. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 52 REFERENCES
Better tolerability of St. John's wort extract WS 5570 compared to treatment with SSRIs: a reanalysis of data from controlled clinical trials in acute major depression
TLDR
WS 5570 was devoid of effects of sedation, anticholinergic reactions, gastrointestinal disturbances, and sexual dysfunction often found during treatment with SSRIs and other synthetic antidepressants. Expand
The treatment of minor depression with St. John's Wort or citalopram: failure to show benefit over placebo.
TLDR
St John's Wort was not responsive to either a conventional antidepressant or a nutraceutical, and both compounds were associated with a notable side effects burden, so other treatment approaches for MinD should be investigated. Expand
A Double-blind, Randomized Trial of St John's Wort, Fluoxetine, and Placebo in Major Depressive Disorder
TLDR
St John's wort was significantly more effective than fluoxetine and showed a trend toward superiority over placebo and appeared to be safe and well tolerated. Expand
Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mildmoderate depression
  • E. Schrader
  • Medicine
  • International clinical psychopharmacology
  • 2000
TLDR
It was concluded that hypericum and fluoxetine are equipotent with respect to all main parameters used to investigate antidepressants in this population and although hypericum may be superior in improving the responder rate, the main difference between the two treatments is safety. Expand
An open-label pilot study of St. John's wort in juvenile depression.
TLDR
St. John's wort may be an effective treatment for youths diagnosed with major depressive disorder and placebo controlled trials seem indicated. Expand
Superior efficacy of St John's wort extract WS® 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298]
TLDR
Hypericum perforatum extract WS®, 5570 at doses of 600 mg/day (once daily) and 1200 mg/ day (600 mg twice daily) were found to be safe and more effective than placebo, with comparable efficacy of the WS® 5570 groups for the treatment of mild to moderate major depression. Expand
Comparison of San John'Wort extract with fluoxetine in the treatment of post-stroke depression
TLDR
Neurostan appears to be effective and safe against post-stroke depression. Expand
Comparison of equivalence between the St. John's wort extract LoHyp-57 and fluoxetine.
TLDR
The antidepressant efficacy of a daily dose of 800 mg of the St. John's wort extract LoHyp-57 was shown to be equivalent to that of 20 mg fluoxetine in elderly patients with mild or moderate depressive episodes according to ICD 10. Expand
Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study.
TLDR
The hypericum extract was at least as effective as sertraline in the treatment of mild to moderate depression in a small group of outpatients. Expand
St John's wort or sertraline? Randomized controlled trial in primary care.
TLDR
The more benign side effects of SJW make it a good first choice for this patient population, and there were no important differences in changes in mean Ham-D and BDI scores between the two groups at 12 weeks. Expand
...
1
2
3
4
5
...